Health Canada has officially eliminated the finished product specification (FPS) submission requirement for Class II and Class III NHP product licence applications, streamlining the application process by reducing the amount of documentation required when seeking market authorization for natural health products in Canada.
The change, effective as of June 15, 2026, is part of a broader effort to modernize the Natural and Non-prescription Health Products Directorate (NNHPD) application process, is expected to reduce administrative burden for applicants and improve application processing efficiency.
This update to the FPS submission requirement for NHP product licence applications reflects a shift in Health Canada approach to pre-market review. Rather than requiring detailed finished product specifications at the application stage, the regulator will rely on other existing quality assurance requirements under the Natural Health Products Regulations, including Good Manufacturing Practices (GMP), as well as post-market compliance and enforcement activities to ensure product quality.
What Has Changed
Previously, applicants for a Class II or Class III NHP product licence were required to include a completed FPS document as part of their submission package. The FPS outlines specifications about the finished dosage form, including identity, quantity, potency, and other quality parameters used to demonstrate that the product met applicable quality requirements.
While the intent was to ensure product quality prior to market entry, the requirement increased the amount of documentation required and could contribute to longer application preparation and review times at the NNHPD. Under the updated process, Health Canada no longer requires applicants to submit an FPS for Class II and Class III NHP product licence applications.
The official guidance from Health Canada confirms that this documentation is no longer a mandatory component of the pre-market submission. Companies are still required to develop and maintain finished product specifications internally as part of their Good Manufacturing Practices (GMP) obligations complying with the Natural Health Products Regulations (NHPR) These specifications must be available to demonstrate compliance during inspections or other regulatory activities, even though they are no longer submitted with the product licence application.
Why Health Canada Made This Change
The decision aligns with Health Canada’s ongoing regulatory modernization efforts, which aim to improve efficiency without compromising safety. Over the past several years, the NNHPD has focused efforts to reduce lengthy review timelines and a growing backlog of product licence applications.
By removing the FPS submission requirement for NHP product licence applications, this allows Health Canada to focus its pre-market review on information that is more directly related to the safety, efficacy, and appropriate use of the product, and in turn reduce administrate burden for both applicants and regulators.
This change also reflects Health Canada’s continued reliance on Good Manufacturing Practices (GMP) and site licensing to ensure product quality. Since licensed NHP manufacturers are already subject to inspection and must maintain product specifications on-site, the regulator has determined that requiring these documents at the application stage represents a duplication of effort. This risk-based approach mirrors trends seen in other regulatory agencies internationally.
Overall, the update reflects a more risk-based and efficient regulatory approach, where product quality continues to be assured through GMP compliance and post-market oversight rather than through the routine submission of finished product specifications during the pre-market licensing process.
What Remains Required in the Application
Although Finished Product Specifications (FPS) are no longer required as part of Class II and Class III Natural Health Product (NHP) Product Licence Applications (PLAs), applicants must continue to submit a complete application that meets all other applicable requirements under the Natural Health Products Regulations (NHPR). Key components of the submission package continue to include:
Medicinal and non-medicinal ingredient details, including quantities per dosage unit
Evidence supporting the product’s safety and efficacy claims, where applicable.
Product label text that complies with NHPR requirements
Information identifying the manufacturing, packaging, labelling, and importation sites, as required under the regulations, and if available at the time of submission.
Health Canada will continue to screen applications for completeness. Companies should ensure that all remaining components are thoroughly prepared to avoid delays during the screening phase, or later on.
Impact on Pending and Future Submissions
For companies with pending Class II or Class III PLAs, the removal of the FPS submission requirement means that Finished Product Specifications are no longer expected as part of the application package. Applicants should follow the current Health Canada guidance applicable at the time of submission or review.
For new applications, companies can omit the FPS document, reducing the amount of documentation required and simplifying dossier preparation, particularly for companies managing large volumes of product submissions. That said, the underlying obligation to develop, and maintain finished product specifications of compliance under GMP have not changed.
These records must be retained and made available to Health Canada upon request during inspections or other compliance and enforcement activities. Health Canada also still holds the right to request an FPS document during the review of an application in relation to risk-related quality issues.
What This Means for Your Business
The removal of the Finished Product Specification (FPS) submission requirement simplifies the preparation of Class II and Class III Natural Health Product (NHP) Product Licence Applications (PLAs). Product licence applicants can expect a more streamlined preparation process, and the change may contribute to faster screening and review cycles at the NNHPD over time. Companies with multiple pending or planned submissions stand to benefit, as the cumulative time savings from omitting FPS documentation across a product portfolio can be substantial.
While this change reduces the administrative burden, this change does not reduce the importance of maintaining rigorous internal quality documentation. Health Canada’s decision to remove the FPS from the pre-market submission process is predicated on the assumption that licensed manufacturers are already meeting their GMP obligations in full.
Companies that have relied on the application process as a forcing function for developing finished product specifications should take this opportunity to audit their internal documentation and ensure that all FPS records are current and compliant as they remain an essential component of an effective GMP program.
Quality Smart Solutions advises NHP companies to review their current PLA submissions and update their standard operating procedures to reflect this change. If your company is uncertain about how this update affects specific applications or internal compliance posture, contact Quality Smart Solutions for guidance tailored to your regulatory situation.
Frequently Asked Questions
Does the removal of the FPS submission requirement mean companies no longer need to create finished product specifications?
This is a common point of confusion following the announcement. The answer is no. Health Canada still requires NHP manufacturers to develop and maintain finished product specifications as part of their GMP obligations under the Natural Health Products Regulations. The change only removes the requirement to include the FPS document for Class II and Class III Natural Health Product (NHP) Product Licence Applications (PLAs); the FPS no longer needs to be submitted with the application package. Inspectors may request FPS documentation during site inspections, and companies that fail to maintain these records could face compliance enforcement.
Will applications that were previously rejected for a missing FPS be reconsidered?
Many applicants who received screening deficiency notices related to FPS documentation are understandably wondering about this. Health Canada has not indicated a blanket policy to retroactively reconsider previously rejected applications solely on this basis. Applicants should follow the instructions provided in their deficiency or refusal notice and consult the current Health Canada guidance to determine the appropriate next steps. If there is uncertainty about how the updated requirements apply to an existing application, applicants may wish to contact the Natural and Non-prescription Health Products Directorate (NNHPD) for clarification.
How does this change affect NHP applications that include novel ingredients or higher-risk claims?
It is reasonable to wonder whether the FPS exemption applies the same way across all product types. Since the exemption is limited to Class II and Class III NHP product licence applications, applications involving novel ingredients or therapeutic claims are typically handled under a different classification and follow a more detailed safety and efficacy review. For products that fall under Class II or Class III, the quality-related scrutiny shifts more heavily toward the GMP inspection process than toward the pre-market submission stage. However, Health Canada still holds the right to request an FPS during the application review process if they deem it necessary.
Key Takeaways
- Effective June 15, 2026, Health Canada has removed the FPS submission requirement for Class II and Class III NHP product licence applications.
- Companies are still required to develop and maintain finished product specifications internally as part of their Good Manufacturing Practices under the Natural Health Product Regulations (NHPR).
- All other components of the NHP product licence application remain in effect, including ingredient details, safety and efficacy evidence, and compliant product labelling.
- The change is expected to reduce preparation complexity and may contribute to shorter NHPD review timelines over time.
- NHP manufacturers should audit their internal FPS documentation to ensure inspection readiness, as Health Canada’s quality assurance focus shifts further toward post-market oversight.
Preparing for the Updated Process
This regulatory change represents a practical step forward in Health Canada’s effort to modernize NHP oversight and reduce unnecessary administrative burden. For companies actively managing product licence submissions, now is the time to update internal procedures, confirm that GMP documentation is inspection-ready, and adjust submission templates accordingly.
If you’re preparing an NHP product licence application or want to confirm how this update affects your current or future submission strategy, our NHP licensing services team can guide you. From product classification and evidence assessments to submission preparation and Health Canada correspondence, QSS walks you through every stage of the licensing process while helping ensure your quality systems remain aligned with current regulatory requirements. Contact us to discuss your specific situation and ensure your application and quality systems reflect current requirements.
